Almudena Coto-VilcapomaLaura Sánchez-CarreteroDaniel Arenas-GonzalezJosé A MolinaMaría José Morán-JiménezPaz de la TorreAna I FloresMerino Martín, José Joaquín2026-05-192026-05-192026Coto-Vilcapoma A, Sánchez-Carretero L, Arenas-Gonzalez D, et al. Protective Effect of Placental Mesenchymal Stromal Cells in an In Vitro Model of Parkinson’s Disease Using Differentiated Neuroblastoma Cells. IJMS 2026;27:3925. https://doi.org/10.3390/ijms2709392510.3390/ijms27093925https://hdl.handle.net/20.500.14352/136752Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder. It is characterized by the accumulation of misfolded α-synuclein (α-syn) and progressive loss of dopaminergic neurons in the substantia nigra. Due to the limitations of current therapies, mesenchymal stromal cell (MSC) transplantation has emerged as a promising neuroprotective strategy. This study evaluated the neuroprotective potential of decidua-derived mesenchymal stromal cells (DMSCs) in vitro using a human neuroblastoma cell line (NB69) exposed to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) as a PD model. The NB69 cells were differentiated into a mature dopaminergic phenotype using dibutyryl cyclic adenosine monophosphate (dbcAMP) and then exposed to MPP+. In proliferative NB69 cells, the effect of DMSCs was masked by their inherent antitumor activity against the neuroblastoma phenotype. Conversely, in the differentiated NB69 model, DMSCs demonstrated a significant protective role against MPP+-induced cytotoxicity. Interestingly, the mechanism by which DMSCs might exert a neuroprotective effect against MPP+ damage in differentiated NB69 cells appears to involve improving mitochondrial function by reducing free radicals. In summary, these findings suggest that DMSCs exert a neuroprotective effect in a dopaminergic-like context and highlight the importance of using differentiated cell models to accurately evaluate cell-based therapies for PD in the striatum.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal articlehttps://doi.org/10.3390/ijms27093925https://pubmed.ncbi.nlm.nih.gov/42123507/open access577.1615.01/.03perinatal mesenchymal stromal cellsperinatal MSCsdecidua mesenchymal stromal cellsDMSCsdibutyryl cyclic adenosine monophosphatedbcAMP1-methyl-4-phenylpyridiniumMPP+NB69ParkinsonPDneuroprotectionoxidative stressFarmacología (Farmacia)Bioquímica (Farmacia)2302.22 Farmacología Molecular